日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Systematic Review of the Molecular Mechanisms Involved in the Association Between PCOS and Endometrial and Ovarian Cancers

多囊卵巢综合征与子宫内膜癌和卵巢癌关联中涉及的分子机制的系统性综述

Zanjirband, M; Nasr-Esfahani, M H; Curtin, N J; Drew, Y; Sharma Saha, S; Adibi, P; Lunec, J

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.

S期PARP抑制可优先增强拓扑异构酶I毒素的细胞毒性

Znojek P, Willmore E, Curtin N J

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

抑制DNA损伤反应作为癌症治疗策略

Curtin, N J

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

聚(ADP-核糖)聚合酶抑制剂在癌症治疗中的应用潜力

Javle, M; Curtin, N J

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

聚(ADP-核糖)聚合酶(PARP)抑制剂NU1025对L1210细胞中拓扑异构酶I和II抑制剂细胞毒性的体外差异性影响

Bowman, K J; Newell, D R; Calvert, A H; Curtin, N J

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.

ADEPT 药物 ZD2767 诱导细胞凋亡:与经典氮芥类药物苯丁酸氮芥和单功能 ZD2767 类似物的比较

Monks N R, Blakey D C, Curtin N J, East S J, Heuze A, Newell D R

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.

双嘧达莫通过抑制胸苷转运增强 MTA (LY231514) 的体外活性

Smith P G, Marshman E, Newell D R, Curtin N J

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding

双嘧达莫类似物通过降低α1-酸性糖蛋白结合能力增强胸苷酸合成酶(TS)抑制剂的细胞毒性

Curtin, N J; Bowman, K J; Turner, R N; Huang, B; Loughlin, P J; Calvert, A H; Golding, B T; Griffin, R J; Newell, D R

Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo

大鼠体内肝癌发生和肝脏再生过程中的酶促逆分化

Curtin, N J; Snell, K